title: Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.
abstract: OBJECTIVE
  Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. Chronic exposure to oxidative stress leads to depletion of liver antioxidants and abnormal cytokine production; antioxidant therapy is one of the main therapeutic lines in NAFLD. In the current study we aimed to investigate the effect of coenzyme Q10 (coQ10) therapy on several adipocytokines and insulin resistance in patients with NAFLD.
  
  
  METHODS
  In the current randomized double-blind placebo controlled trial 44 NAFLD patients were enrolled. After randomization into two groups, 22 patients received 100 mg/day coQ10 capsules and 22 patients received placebo daily for 4 weeks. BMI and WHR were calculated for patients at the beginning and end of the study and blood samples were obtained from the patients to measure serum concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting serum glucose (FSG), insulin resistance (IR), vaspin, chemerin, pentraxin 3 (PTX3) and markers of oxidative stress including total antioxidant capacity (TAC) and malondialdehyde (MDA).
  
  
  RESULTS
  After 4 weeks of coQ10 supplementation, waist circumference (WC) and serum AST and TAC concentrations significantly decreased in intervention group (p <0.05) but no significant changes occurred in placebo-treated group. In stepwise multivariate linear regression model, change in serum FSG was a significant predictor of changes in serum vaspin, chemerin and pentraxin 3 (p <0.001).
  
  
  CONCLUSIONS
  The present study showed a potential for coQ10 therapy in improving several anthropometric and biochemical variables in NAFLD. Longer studies with higher doses of coQ10 are required to further evaluate this potential benefit.
authors.affiliation: Department of Community Nutrition, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Mahdieh Abbasalizad
authors.initials: MA
authors.lastname: Farhangi
authors.affiliation: Department of Community Nutrition, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: alipourb@tbzmed.ac.ir.
authors.forename: Beytollah
authors.initials: B
authors.lastname: Alipour
authors.affiliation: Department of Community Nutrition, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Elnaz
authors.initials: E
authors.lastname: Jafarvand
authors.affiliation: Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Manouchehr
authors.initials: M
authors.lastname: Khoshbaten
mesh_terms: D054392:Adipokines / Q000097:blood; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000975:Antioxidants / Q000008:administration & dosage*; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose; D002097:C-Reactive Protein / Q000032:analysis*; D018925:Chemokines / Q000097:blood*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*; D018384:Oxidative Stress / Q000187:drug effects; D015843:Serpins / Q000097:blood*; D000683:Serum Amyloid P-Component / Q000032:analysis*; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D055105:Waist Circumference / Q000187:drug effects; D055815:Young Adult; D000099153:Pentraxins
chemical_list: D054392:Adipokines; D000410:Alanine Transaminase; D000975:Antioxidants; D001219:Aspartate Aminotransferases; D015415:Biomarkers; D001786:Blood Glucose; D002097:C-Reactive Protein; D018925:Chemokines; D036341:Intercellular Signaling Peptides and Proteins; D015843:Serpins; D000683:Serum Amyloid P-Component; D014451:Ubiquinone; D000099153:Pentraxins; C478630:RARRES2 protein, human; C507339:SERPINA12 protein, human; C024989:coenzyme Q10
keywords: Coenzyme Q10; Insulin resistance; Nonalcoholic fatty liver disease (NAFLD); Oxidative stress